Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of tamoxifen and irinotecan therapies.

Clinics in laboratory medicine - 1 Dec 2008

Algeciras-Schimnich Alicia, O'Kane Dennis J, Snozek Christine L H

Abstract excerpt

Genetic variability in drugmetabolizing enzymes affects the toxicity and efficacy of many compounds, including the chemotherapeutic agents irinotecan and tamoxifen. The correlation of clinical response to polymorphisms in enzymes associated with metabolism of these two drugs has led to the recomm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Pharmacogenetics

Share to Tamoxifen

Source

Identifiers

PMID: 19059062
DOI: 10.1016/j.cll.2008.05.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19059062-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of tamoxifen and irinotecan therapies.PMID 19059062Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 pharmacogenomics of tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 pharmacogenomics of tamoxifen treatment.Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.